149 – Future Trends in Digital Pharma (S10E14)

Welcome to the deep dive. Get ready, because
today we're taking a look into the future, the
future of making medicines. That's right. We're
focusing on how digital tech is set to really
shake things up in pharmaceutical development
over, say, the next decade. And we're aiming
to give you the key takeaways, the important
stuff, drawing from solid research and some real
world examples. Think of it as your shortcut
to getting up to speed. Exactly. No need to get
lost in the weeds. Our goal is simple. Pull out
the most crucial insights on these digital trends,
the innovations, and we'll have a long -term
impact on how drugs get discovered and developed.
OK, let's dive in then. One of the first big
things, it seems, is how all these different
digital tools are starting to work together.
It's not just one thing here, one thing there
anymore. Right, it's more of a convergence. And
what's really interesting is how tools from,
well, outside traditional pharma are becoming
so important. Like, think about the Human Genome
Project. Ah, OK, that really laid the groundwork.
It absolutely did. It gave us things like gene
chips, microarrays, which let us look at, I mean,
thousands of gene activities all at once. Wow.
And similarly, for proteins, we have techniques
like two -dimensional electrophoresis combined
with mass spectrometry. It gives you a real detailed
map of the proteins involved when a drug hits
the system. So it helps understand toxicity,
things like that. Precisely. Understanding those
mechanisms at a molecular level. But I imagine
that creates just a ton of data, right? Is that
manageable? Well, that's the catch. The sheer
volume of information from these large -scale
analyses is frankly Enormous. Interpreting it.
Finding the meaningful signals. That's the primary
difficulty. OK, so you need serious digital power
just to make sense of it all. You absolutely
do. Which brings us nicely to the role of computational
tools, even in the very early stages, like designing
the drug molecules themselves. You mean like
computer aided design. Exactly. Things like molecular
docking calculations. It's like virtually testing
how well a drug candidate might fit its target
protein. A bit like trying keys in a lock, but
on screen. And then there's QSR quantitative
structure activity relationship, methods like
COMFO, COMSSE. They use models to predict how
tweaking a molecule structure might affect what
it does biologically. That sounds incredibly
useful for speeding things up. Are there concrete
examples? Oh, definitely. The work on Intel inhibitors
for tuberculosis is a good one. They use these
kinds of computer -aided approaches, docking
and QSR, to figure out which structural features
really mattered. And that allowed for a more
rational design of new candidates aiming for
better potency, maybe fewer side effects based
on the modeling. So much less trial and error,
more intelligent design upfront. That makes sense.
And you can't talk digital without mentioning
AI, artificial intelligence. No, you really can't.
AI's potential here is, well, it's huge. especially
for spotting patterns in enormous data sets.
Think about global clinical trials, masses of
data. AI can help automate that analysis, find
subtle trends maybe humans would miss, and basically
augment the researcher's ability to make good
decisions faster. Like a super -powered research
assistant. Okay, so that's discovery and early
design. What about later on in development and
manufacturing? I've heard about this quality
by design idea. Yes, quality by design or QBD.
It's a really fundamental shift, actually, moving
towards a more science -based, risk -based approach.
OK, what does that mean in practice? Less testing
at the end. Sort of. It means understanding and
controlling the critical factors in the formulation
in the manufacturing process that actually impact
the final drug quality, building quality in from
the start. Got it. Baking it in, not just inspecting
it out. How does digital help with that? That's
where models come in again. Data -driven models,
key metric ones like PCA and PLS, are used a
lot with analytical data, and especially with
PYETT. PYETT. Process Analytical Technology.
Basically monitoring quality during the manufacturing
process in real -time, not just testing the finished
pills or vials. Ah, real -time monitoring. Okay,
that sounds like a potential game changer. It
really can be. You can make adjustments on the
fly if something starts to drift. But crucially,
These models, these chemometric models, they're
only as good as the data you feed them. Right.
Garbage in, garbage out, basically. Yeah. You
need high quality data that really represents
all the possible variations you might see during
normal operation within your design space. Okay.
Robust data is key. And you mentioned models.
Are they also used to understand how drugs work
in people? Because everyone reacts differently,
right? Exactly. That variability between individuals
is critical. And yes, we use mixed effects models
quite a bit in clinical pharmacology for that.
Mixed effects models. Yeah, there are statistical
models that help us understand that individual
variability. So take a simple pharmacokinetic
model, how the body handles a drug. A mixed effects
model can help figure out why one person eliminates
the drug faster than another, even if they seem
similar. It helps refine dosing, understand patient
factors. Fascinating. So you can get a more personalized
understanding, almost. OK, let's shift to the
studies themselves, preclinical and clinical
trials. How is digitalization impacting those?
Well, in preclinical, Biomarkers are increasingly
used in toxicity screening. They help rank new
drug candidates early on based on potential harm
signals. So earlier red flags? Potentially, yes.
And then for clinical trials, especially the
big global ones, you just have massive data flows.
So sophisticated data management systems, often
cloud -based platforms, are absolutely essential.
Organizing it all is a huge task. I can only
imagine coordinating across different countries,
different sites. It's complex. And beyond just
management, digital tools are enabling smarter
trial designs, like adaptive randomization. Adaptive.
What does that mean? It means the trial can...
sort of learn as it goes based on the results
coming in, how patients are assigned to different
treatment groups can be adjusted. You see it
in some cancer trials, for example. If one treatment
arm is clearly doing better early on, maybe more
new patients get assigned to that arm. It can
potentially speed things up. Makes sense. But
what about the treatments themselves getting
more complex? Biologics, gene therapies, AI -designed
drugs even? That's a really important point.
These new modalities bring new challenges for
monitoring and safety. They might have unique
side effects or mechanisms. So our safety protocols,
our monitoring strategies, they have to keep
evolving too. We need robust data, especially
on things like immune responses with biologics,
to really understand the long -term picture.
Constant adaptation needed. Okay, let's circle
back to manufacturing and quality. We mentioned
pat -process analytical technology. How does
that change things on the factory floor? It really
shifts the focus away from just testing the final
product off the line towards building monitoring
into line using sensors, maybe spectroscopic
ones to check quality attributes continuously
in real time. So you catch problems sooner. Exactly.
Less waste, more consistent quality, faster release.
It moves quality control upstream. And I guess
digital helps optimize the process itself, too.
Definitely. Statistical experimental design is
a powerful tool here. You can systematically
test how changing input variables like temperature,
feed rate, whatever it is, affects your outputs,
like yield or purity. Like running controlled
experiments on the process. Precisely. Data -driven
experimentation to find that sweet spot, the
optimal operating conditions for reliable high
-quality production. Okay. And one last connection
linking lab tests to what happens in the body.
I think you mentioned IVI -VC. Yes, in vitro
-in vivo correlation. It's crucial. It's about
finding a predictable link between how a drug
performs in a lab test, like how fast a tablet
dissolves, the in vitro part, and how it actually
gets absorbed and performs in the body, the in
vivo part. How do you model that? Often with
mathematical models, things like differential
equations, convolution integrals, they help describe
that relationship. If you have a good IVIVC,
you can be more confident that your lab tests
predict real -world performance. So it bridges
that gap between the lab bench and the patient.
Makes sense. Wow. Okay, so reflecting on all
this, digital is really touching every single
part of the process, isn't it? It truly is. From
the earliest idea for a molecule through all
the testing, the clinical trials, manufacturing,
quality control, it's becoming deeply integrated.
And the potential benefits are pretty clear,
efficiency, better understanding, hopefully faster
access to new medicines? Yeah, the pace of change
seems incredible. It really makes you think about
what's next, doesn't it? We've talked about AI
and data, but Looking ahead, what happens when
these tools get even more sophisticated? Could
we see, I don't know, AI taking an even more
autonomous role in designing drugs or even managing
aspects of clinical trials? What might that look
like? That's a really fascinating question to
ponder, isn't it? The trajectory certainly points
towards more integration, more capability. It
definitely raises questions about the future
balance between human oversight and machine intelligence
in this field. Something to keep an eye on. Definitely
food for thought. Well, this has been incredible.
incredibly insightful. Thanks so much for walking
us through this complex landscape. My pleasure.
It's certainly a dynamic area, always changing.
And a big thank you to our listeners for joining
us on this deep dive into the future of digital
pharma. We hope it gave you a clear picture of
these exciting transformations. Join us next
time for another deep dive.